Compare NSPR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSPR | IFRX |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 81.3M |
| IPO Year | N/A | 2017 |
| Metric | NSPR | IFRX |
|---|---|---|
| Price | $1.59 | $1.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $4.00 | ★ $8.50 |
| AVG Volume (30 Days) | 48.1K | ★ 656.0K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,779,000.00 | $73,729.00 |
| Revenue This Year | $22.76 | N/A |
| Revenue Next Year | $75.45 | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.04 | N/A |
| 52 Week Low | $1.58 | $0.71 |
| 52 Week High | $3.80 | $2.77 |
| Indicator | NSPR | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.92 | 43.09 |
| Support Level | $1.78 | $0.99 |
| Resistance Level | $1.95 | $1.16 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 12.12 | 13.04 |
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.